Company Overview
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and rheumatology and allergy.
GRAFAPEX, an alkylating drug indicated for use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation, represents a significant growth opportunity for Medexus. This is driven by its potential to address unmet needs in transplant medicine and expand the company’s presence within hematology-oncology. With increasing adoption across transplant centers, GRAFAPEX could become a key driver of revenue growth and long-term value creation for the company.
Upcoming Event
LD Micro Invitational XVI
Treosulfan Pivotal Study Results with Dr. Filippo Milano, MD
Email Alerts
Receive updates straight into your inbox
Investor Contact Information
Company
Medexus Pharmaceuticals, Inc.
10 King Street East, Suite 600
Toronto, ON M5C 1C3
Canada
T: 877-422-5242
Investor Relations
Adelaide Capital
Victoria Rutherford
T: 480-625-5772
Victoria@adcap.ca
Direct Financial Strategies and Communication Inc.
Frank Candido
T: 514-969-5530
frank@directfinancial-ir.com